Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumer

Downloads

Life Saving Drugs Program – Fabry disease – Review summary and expert panel recommendations for consumers

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Publication type:
Procedure
Audience:
General public
Language:
English

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.